Michelle Rengarajan MD
Endocrinology
Fellow at Massachusetts General Hospital
Join to View Full Profile
55 Fruit StBoston, MA 02114
Phone+1 617-726-3872
Fax+1 617-726-5905
Dr. Rengarajan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2018 - 2022
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2016 - 2018
Stanford University School of MedicineClass of 2016
Certifications & Licensure
MA State Medical License 2016 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Publications & Presentations
PubMed
- Concerns in Interpretation of Results In the Identification of Immune Checkpoint Inhibitor-Induced Diabetes-Reply.Karina N Ruiz-Esteves, Aaron J Deutsch, Michelle Rengarajan
JAMA Oncology. 2025-03-01 - 3 citationsIdentification of Immune Checkpoint Inhibitor-Induced Diabetes.Karina N Ruiz-Esteves, Kaitlyn R Shank, Aaron J Deutsch, Alekhya Gunturi, Natalia Chamorro-Pareja
JAMA Oncology. 2024-10-01 - 1 citationsCase 6-2022: A 68-Year-Old Man with Fatigue, Weight Loss, and Hyperglycemia.Jonathan R Wing, Allison Kimball, Michelle Rengarajan
The New England Journal of Medicine. 2022-02-24
Press Mentions
Identification of Immune Checkpoint Inhibitor–Induced DiabetesAugust 29th, 2024
Grant Support
- Modulation of immune cell phenotype by hormone-producing epithelia in autoimmune endocrinopathiesMASSACHUSETTS GENERAL HOSPITAL2022–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
